PARIS – Results from a 2-year follow-up analysis of the EARLY-TAVR trial show patients who have early transcatheter aortic valve replacement (TAVR) show improvement in cardiac damage compared with baseline, but patients in the clinical surveillance (no TAVR) group have worsening cardiac damage.